261 related articles for article (PubMed ID: 28656798)
1. Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction.
Ennezat PV; Cosgrove S; Marechaux S; Bouvaist H; Le Jemtel TH; Vital Durand D
Acta Cardiol; 2017 Dec; 72(6):664-668. PubMed ID: 28656798
[TBL] [Abstract][Full Text] [Related]
2. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
[TBL] [Abstract][Full Text] [Related]
3. Novel drugs for heart rate control in heart failure.
Bielecka-Dabrowa A; von Haehling S; Rysz J; Banach M
Heart Fail Rev; 2018 Jul; 23(4):517-525. PubMed ID: 29594814
[TBL] [Abstract][Full Text] [Related]
4. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
Weeda ER; Nguyen E; White CM
Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
[TBL] [Abstract][Full Text] [Related]
5. [From results of BEAUTIFUL trial to results of SHIFT trial: BEAUTIFUL possibility to make a SHIFT in current guidelines].
Lopatin IuM
Kardiologiia; 2011; 51(5):85-90. PubMed ID: 21649600
[TBL] [Abstract][Full Text] [Related]
6. Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
Marciniak TA; Atar D; Serebruany V
Am J Med; 2020 Mar; 133(3):347-351. PubMed ID: 31442391
[TBL] [Abstract][Full Text] [Related]
7. Ivabradine: Do the Benefits Outweigh the Risks?
Alshammari TM
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):210-218. PubMed ID: 27698078
[TBL] [Abstract][Full Text] [Related]
8. Effects of adding ivabradine to usual care in patients with angina pectoris: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.
Maagaard M; Nielsen EE; Sethi NJ; Ning L; Yang SH; Gluud C; Jakobsen JC
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33046592
[TBL] [Abstract][Full Text] [Related]
9. The effects of heart rate control in chronic heart failure with reduced ejection fraction.
Grande D; Iacoviello M; Aspromonte N
Heart Fail Rev; 2018 Jul; 23(4):527-535. PubMed ID: 29687317
[TBL] [Abstract][Full Text] [Related]
10. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R
Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC
ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
[TBL] [Abstract][Full Text] [Related]
13. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study.
Tsutsui H; Momomura SI; Yamashina A; Shimokawa H; Kihara Y; Saito Y; Hagiwara N; Ito H; Yano M; Yamamoto K; Ako J; Inomata T; Sakata Y; Tanaka T; Kawasaki Y;
Circ J; 2019 Sep; 83(10):2049-2060. PubMed ID: 31391387
[TBL] [Abstract][Full Text] [Related]
15. Rate control with ivabradine: angina pectoris and beyond.
Parakh N; Bhargava B
Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
[TBL] [Abstract][Full Text] [Related]
16. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
18. The Role of Ivabradine in the Management of Angina Pectoris.
Giavarini A; de Silva R
Cardiovasc Drugs Ther; 2016 Aug; 30(4):407-417. PubMed ID: 27475447
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine: beyond heart rate control.
Riccioni G; Vitulano N; D'Orazio N
Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
[TBL] [Abstract][Full Text] [Related]
20. [Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?].
Kanorskiy SG; Borisenko YV
Kardiologiia; 2018 Jun; 58(6):85-89. PubMed ID: 30362441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
